Please login to the form below

Not currently logged in
Email:
Password:

empagliflozin

This page shows the latest empagliflozin news and features for those working in and with pharma, biotech and healthcare.

Boehringer Ingelheim/Lilly’s empagliflozin is first drug to show clear benefit in heart failure

Boehringer Ingelheim/Lilly’s empagliflozin is first drug to show clear benefit in heart failure

Empagliflozin also reduced the relative risk of first and recurrent hospitalisations for heart failure by 27% and significantly slowed kidney function decline. ... underlines empagliflozin’s potential for improvement in patients’ quality of life and

Latest news

More from news
Approximately 17 fully matching, plus 84 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Viseven

Viseven is a Global MarTech Services Provider for Pharma and Life Sciences Industries...

Latest intelligence

Five big changes in the healthcare comms landscape
The world of healthcare has changed very greatly in the five years since The Difference Collective launched. Our agile model and talented team have enabled us to keep pace with...
Early communications in Pharma: How effective pre-approval comms delivers launch success
What communications are required for a successful launch...
Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....